Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2016 -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a biopharmaceutical company developing novel treatments for nonalcoholic steatohepatitis (NASH), and other serious immuno-inflammatory and fibrotic diseases, will report financial results for the quarter ended December 31, 2015 after market close on Thursday March 3, 2016. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Date: March 3, 2016
Time: 1:30 PM PT
Listen via Internet: http://ir.tobiratherapeutics.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=71315&k=7CAD412C
Toll-free: 1 (855) 638-8858
International: +1 (707) 294-1299
Password: 47016109
A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 47016109.
About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at www.tobiratherapeutics.com.
CONTACT: Tobira Investor & Media Contact
Ian Clements, PhD
+1 (650) 351-5013
[email protected]
Canale Communications Media Contact
Pam Lord
+1 (619) 849-6003
[email protected]
